Jeffrey Zucker brings more than 25 years of experience in clinical research operations across sites, Sponsors, CROs, and technology partners. Trained as a psychotherapist with a specialty in industrial dynamics, he combines behavioral insight with hands-on experience optimizing feasibility, patient recruitment, rater quality, and site performance across neuroscience and complex clinical trial environments.
Throughout his career, Jeff has led global feasibility, site management, and trial optimization teams at organizations including Worldwide Clinical Trials, ICON, INC Research, and Eli Lilly. His work spans nearly every therapeutic area and study phase, with a notable focus on CNS, including depression, anxiety disorders, Alzheimer’s disease, schizophrenia, and rare diseases.
Jeff’s experience across operations, rater-dependent study oversight, investigator relations, and patient recruitment strategy gives him a practical, systems-level approach to rater reliability and operational readiness. As Tekton’s Chief Development Officer and CNS consultant, he supports teams in strengthening scale administration quality, site consistency, and operational performance so CNS trials can produce reliable, high-integrity data.
